Indivior Europe

Indivior Europe Limited is the European subsidiary of Indivior, a global specialty pharmaceutical company focused on developing and commercializing treatments for substance use disorders, particularly opioid use disorder (OUD). Headquartered in Dublin, Ireland, Indivior Europe has historically held marketing authorizations and managed the commercial distribution of core products like Suboxone and Subutex across various European markets, including Sweden, the UK, Ireland, Finland, and Italy. However, following a strategic review by the parent company in late 2025, Indivior announced plans to withdraw these anti-addiction medications from several European countries to focus resources on its priority US market. Additionally, the company's recent pipeline updates in 2026 include the discontinuation of internal development for its Phase 2 candidates INDV-2000 and INDV-6001.